Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2022

Le sécukinumab dans l'arthrite liée à l'enthésite et le rhumatisme psoriasique juvénile : Essai de phase 3 randomisé, en double aveugle, contrôlé par placebo, avec arrêt de traitement

Ann Rheum Dis. 2022 2022 2022-222849

Calvo Penades I,

Rakhimyanova A,

Ruperto N; Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)

In the latest study by Brunner, et al. secukinumab demonstrated efficacy and safety in the JIA categories of ERA and JPsA. This phase 3 study aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA.

Keywords: